CN111067884A - Pharmaceutical composition and application thereof - Google Patents
Pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN111067884A CN111067884A CN202010025091.XA CN202010025091A CN111067884A CN 111067884 A CN111067884 A CN 111067884A CN 202010025091 A CN202010025091 A CN 202010025091A CN 111067884 A CN111067884 A CN 111067884A
- Authority
- CN
- China
- Prior art keywords
- adriamycin
- caffeic acid
- group
- pharmaceutical composition
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of biological medicine, in particular to a pharmaceutical composition and application thereof. The pharmaceutical composition provided by the invention remarkably reduces the myocardial cell damage caused by adriamycin in the SD suckling mouse myocardial cell injury test, and improves the cell activity; after detecting the activity of mitochondrial ATP of the cardiac muscle cells after the combined application, the combination of caffeic acid and adriamycin is found to enhance Na in the cardiac muscle cells+‑K+-ATPase and Ca2+-ATPase activity. The caffeic acid and adriamycin can be used for preventing and treating myocardial damage caused by adriamycin. Enhancing activity of myocardial cell after injury, reducing injury degree and apoptosis rate of myocardial cell, protecting myocardial cell mitochondria, reducing adverse side effect of adriamycin, and enlargingThe clinical application range of the adriamycin.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to a pharmaceutical composition and application thereof.
Background
Adriamycin (DOX), also known as doxorubicin, is an anthracycline tumor antibiotic, can inhibit the synthesis of DNA and RNA, has a wide antitumor spectrum, and has killing effect on tumor cells of various growth cycles. It is mainly suitable for treating solid tumors such as acute leukemia, malignant lymphoma, breast cancer, etc. However, the clinical application process, which produces severe damage to cardiac muscle cells, can seriously affect the physical health of patients and even threaten the life safety of patients. Therefore, how to develop new drugs for inhibiting doxorubicin cardiotoxicity has been an important issue in medicine.
Caffeic Acid (CA) is a natural phenolic compound, widely exists in plant bodies, can be safely used in cosmetics, has wide antibacterial and antiviral activities, is mainly a medicine for stopping bleeding and increasing leucocytes, and has the functions of contracting and reinforcing capillaries, improving blood coagulation factors and increasing leucocytes and thrombocytes. In recent years, there have been reports in the literature that caffeic acid may be used for ameliorating symptoms such as oxidative stress, inflammatory reaction, and viral infection. However, at present, whether caffeic acid has a protective effect on adriamycin myocardial damage or not and a specific mechanism thereof have no literature report.
Disclosure of Invention
In order to solve the above technical problems, the present invention aims to provide a combination drug which can better alleviate drug-induced myocardial damage caused by adriamycin. The test result of the invention shows that the combined application of the caffeic acid and the adriamycin can obviously relieve the myocardial damage caused by the adriamycin, thereby reducing the adriamycin myocardial cytotoxicity, and the combined application of the caffeic acid and the adriamycin can be used for preventing and treating the myocardial cell damage caused by the adriamycin and expanding the clinical application range of the adriamycin.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a pharmaceutical composition comprising caffeic acid and adriamycin.
In some embodiments of the invention, the molar ratio of caffeic acid to doxorubicin is 0.25-3: 1.
In some embodiments of the invention, the molar ratio of caffeic acid to doxorubicin is 1.5: 1.
The invention also provides application of the pharmaceutical composition in preparation of drugs for treating drug-induced cardiomyopathy. Further, the drug-induced cardiomyopathy is cardiomyopathy caused by adriamycin.
The invention also provides a medicament for treating drug-induced cardiomyopathy, which comprises the medicinal composition.
Further, the molar ratio of caffeic acid to adriamycin in the medicine is 0.25-3: 1;
1. further preferably, the molar ratio of caffeic acid to adriamycin in the medicament is 0.25-3: 1. Further, the drug-induced cardiomyopathy is a myocardial injury disease caused by adriamycin.
The invention also provides application of the composition in preparing a medicament for preventing and treating myocardial cell damage caused by adriamycin.
The pharmaceutical composition provided by the invention remarkably reduces the myocardial cell damage caused by adriamycin in the SD suckling mouse myocardial cell injury test, and improves the cell activity; after detecting the ATP enzyme activity of mitochondria of the cardiac muscle cells after the medicine is taken, the combination of caffeic acid and adriamycin is found to enhance Na in the cardiac muscle cells+- K+-ATPase and Ca2+-ATPase activity.
Compared with the prior art, the invention has the beneficial effects that:
a series of test results prove that the combined use of the caffeic acid and the adriamycin can obviously improve the activity of the myocardial cells and reduce the myocardial cell injury and apoptosis caused by the adriamycin. The combined application of caffeic acid and adriamycin is found to enhance Na in the myocardial cells through the detection of cell mitochondrial ATPase activity+- K+-ATPase and Ca2+-ATPase activity to protect cardiomyocyte mitochondria. Based on the research results, the combined use of caffeic acid and adriamycin can prevent and treat myocardial damage caused by adriamycin. The method has the advantages of enhancing the activity of the damaged myocardial cells, reducing the damage degree and the apoptosis rate of the myocardial cells, protecting the mitochondria of the myocardial cells, reducing the side effect of the adriamycin and expanding the clinical application range of the adriamycin.
Drawings
FIG. 1 is a graph comparing the results of myocardial cell injury experiments in various groups;
FIG. 2 is a comparison of OD values of nucleosome contents in lysates of various groups of myocardial cells;
FIG. 3 shows the respective groups Na in example 4+- K+-a comparison of ATPase activity;
FIG. 4 shows groups of Ca in example 42+Comparison of ATPase activity.
Detailed Description
The invention discloses a pharmaceutical composition and application thereof, and can be realized by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention. The pharmaceutical composition and the raw materials and reagents used in the application thereof provided by the invention are all available in the market. The SD suckling mouse is provided by the experimental animal center of Jiangsu university; doxorubicin, caffeic acid, pancreatin were purchased from Sigma; 10% fetal bovine serum was purchased from Hyclone; DMEM medium was purchased from Gibico.
Example 1: effect of caffeic acid on Activity of Adriamycin-damaged cardiomyocytes
Taking SD suckling mice on one day of birth, taking the heart tip part after being sterilized and killed, and obtaining the myocardial cells by conventional digestion of pancreatin. Suspending the cardiomyocytes in DMEM medium containing 10% fetal calf serum at 37 deg.C with 5% CO2The resulting cardiomyocytes were purified after 2h of culture. According to 105one/mL of the cells was inoculated into a 96-well plate and cultured for another 48 h. The purified cardiomyocytes were randomly divided into 8 groups, which were a normal control group, an adriamycin group (DOX), a caffeic acid group (CA), and 5 groups of adriamycin + caffeic acid mixed groups (DOX + CA) with different concentrations. Dissolving adriamycin with normal saline to obtain a final concentration of 10 μ M; caffeic acid was dissolved in preheated double distilled water to a final concentration of 30 μ M and then diluted to the desired concentration in each group. Each set of detailed information is as follows:
① Control group (Control group) 200. mu.L DMEM
② doxorubicin group (1. mu.M) 180. mu.L DMEM + 20. mu.L DOX
③ caffeic acid (0.25 μ M) + doxorubicin group (1 μ M) 160 μ L DMEM +20 μ L CA +20 μ L DOX
④ caffeic acid (0.5 μ M) + doxorubicin group (1 μ M) 160 μ L DMEM +20 μ L CA +20 μ L DOX
⑤ caffeic acid (1 μ M) + doxorubicin group (1 μ M) 160 μ L DMEM +20 μ L CA +20 μ L DOX
⑥ caffeic acid (1.5 μ M) + doxorubicin group (1 μ M) 160 μ L DMEM +20 μ L CA +20 μ L DOX
⑦ caffeic acid (3 μ M) + doxorubicin group (1 μ M) 160 μ L DMEM +20 μ L CA +20 μ L DOX
⑧ caffeic acid (3. mu.M) group 180. mu.L DMEM + 20. mu.L CA.
The myocardial cells of the above groups were incubated at 37 ℃ with 5% CO2After 24h incubation in the incubator 20. mu.L MTT (5mg/mL) was added per well. Note: MTT is unfrozen before use, and MTT is sensitive to light and can be operated under the condition of no light as far as possible. After 3-4h of incubation, the incubation was terminated and the culture medium in the wells was carefully aspirated. Add 150. mu.L of dimethyl sulfoxide (DMSO) per well and incubate at 37 ℃ for 10 min in an incubator or shake the shaker for 10 min at low speed. Then detecting OD by using a microplate reader490nmThe absorbance (A) value of each well was measured, and the cell viability was measured.
The results of the experiments are shown in Table 1, and the cell viability of the doxorubicin group is lower than that of the Control group (C:)P<0.05), the cell activity of the adriamycin and caffeic acid mixed group is higher than that of the adriamycin group, and the adriamycin and caffeic acid mixed group has certain dose dependence; the cell viability of the single caffeic acid group is similar to that of the Control group, and therefore, the myocardial cell viability is remarkably improved after the caffeic acid and the adriamycin are combined.
TABLE 1 statistics of cardiomyocyte viability
Grouping | Cell survival rate (%) |
Control | 90.2±5.4 |
DOX | 44.6±7.1# |
CA(0.25μM)+DOX | 50.8±6.3* |
CA(0.5μM)+DOX | 49.3±2.7* |
CA(1μM)+DOX | 53.8±8.1* |
CA(1.5μM)+DOX | 60.8±6.2* |
CA(3μM)+DOX | 57.2±7.3* |
CA(3μM) | 91.1±6.0# |
In comparison with the Control group,# P<0.05; compared with the DOX group, the method has the advantages that,* P<0.05。
example 2 Effect of caffeic acid on myocardial cell injury caused by Adriamycin
The cardiomyocytes grouped in example 1 were incubated at 37 ℃ with 5% CO2After incubation in an incubator for 24h, cell supernatants of each group are extracted, and the Lactate Dehydrogenase (LDH) content in each group is detected by a full-automatic biochemical analyzer. FIG. 1 is a graph comparing the results of myocardial cell injury experiments in various groups; as shown in FIG. 1, the LDH content in the supernatant of DOX group was 36.87. + -. 1.86U/mL, which is much higher than that of Control group (6.92. + -. 0.37U/mL), while the LDH content in each of CA + DOX group was lower than that of DOX group, andexhibit some dose dependence; the LDH content of the CA group is close to that of the Control group, compared with that of the Control group,* P<0.05; compared with the DOX group, the method has the advantages that,# P<0.05. therefore, the adriamycin causes damage or death of the myocardial cells, the caffeic acid has no influence on the damage of the myocardial cells, and the caffeic acid and the adriamycin can inhibit the damage of the myocardial cells after being used together in a certain range.
Example 3 Effect of caffeic acid on Adriamycin-induced apoptosis of myocardial cells
The cardiomyocytes grouped in example 1 were incubated at 37 ℃ with 5% CO2After incubation in an incubator for 24h, OD values reflecting nucleosome content (nucleosome can reflect apoptosis) in the lysate were detected in the ElISA manner. Note: after cell lysis, high speed centrifugation is required, and nucleosomes are contained in supernatant fluid of the cells.
FIG. 2 is a comparison of OD values of nucleosome contents in lysates of various groups of myocardial cells; as shown in FIG. 2, the OD value of the supernatant of DOX group is 0.88 + -0.013, which is much higher than that of Control group (0.38 + -0.013), while the OD value in each CA + DOX group is lower than that of DOX group and shows a certain dose dependence; OD values of the CA group and the Control group are close to each other, compared with the Control group,* P<0.05; compared with the DOX group, the method has the advantages that,# P<0.05. therefore, the adriamycin causes the apoptosis of the myocardial cells, compared with the control group, the caffeic acid has no influence on the myocardial cells, and the caffeic acid in a certain concentration range can inhibit the apoptosis of the myocardial cells after being combined with the adriamycin.
Example 4 Effect of caffeic acid on myocardial cell mitochondrial injury caused by Adriamycin
Taking SD suckling mice on one day of birth, taking the heart tip part after being sterilized and killed, and obtaining the myocardial cells by conventional digestion of pancreatin. Suspending the cardiomyocytes in DMEM medium containing 10% fetal calf serum at 37 deg.C with 5% CO2The resulting cardiomyocytes were purified after 2h of culture. According to 2.5X 105one/mL of the cells was inoculated in a 24-well plate and cultured for another 48 h. The cardiomyocytes were randomly divided into 3 groups, namely a normal control group, an adriamycin group (DOX), a caffeic acid group (CA) and 5 groups of adriamycin + caffeic acid mixed groups (DOX + CA) with different concentrations. Dissolving adriamycin with normal saline to obtain a final concentration of 10 μ M; dissolution of caffeic acidThe final concentration of the solution was 30. mu.M in preheated double distilled water, and the solution was diluted to the desired concentration in each group. Each set of detailed information is as follows:
① Control group (Control group) 1000. mu.L DMEM
② doxorubicin group (1. mu.M) 900. mu.L DMEM + 100. mu.L DOX
③ caffeic acid (1.5 μ M) + doxorubicin group (1 μ M) 800 μ L DMEM +100 μ L CA +100 μ L DOX.
The grouped myocardial cells were 37 ℃ and 5% CO2After incubation in the incubator for 24h, the cells were disrupted with PBS buffer as a homogenization medium, and the supernatant was centrifuged. Performing enzymatic reaction, determining phosphorus, adjusting color of double distilled water to zero at 660nm with spectrophotometer with light path of 1cm, measuring absorbance value, and calculating mitochondria Na by phosphorus standard curve+- K+-ATPase and Ca2+-ATPase activity.
FIG. 3 shows Na in each group+- K+-a comparison of ATPase activity; FIG. 4 shows Ca in each group2+-a comparison of ATPase activity; as shown in FIG. 3, mitochondrial Na of the DOX group+- K+ATPase activity 0.63. + -. 0.14U/mL, much lower than that of Control (1.69. + -. 0.18U/mL), and mitochondrial Na in CA + DOX+- K+The ATPase activity is 1.06 +/-0.21U/mL, the activity is higher than that of the DOX group, and compared with that of the Control group,* P<0.05; compared with the DOX group, the method has the advantages that,# P<0.05. as shown in FIG. 4, group DOX mitochondrial Ca2+The ATPase activity is 1.99 +/-0.44U/mL, the activity is far lower than that of the Control group 3.83 +/-0.28U/mL, and the CA + DOX group mitochondrial Na+- K+-atpase activity 2.95 ± 0.13U/mL, higher than that of DOX group; in comparison with the Control group,* P<0.05; compared with the DOX group, the method has the advantages that,# P<0.05。
it will be understood by those skilled in the art that the foregoing is only a preferred embodiment of the present invention and is not intended to limit the present invention, and that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention.
Claims (7)
1. A pharmaceutical composition characterized by: including caffeic acid and doxorubicin.
2. The pharmaceutical composition according to claim 1, wherein the molar ratio of caffeic acid to doxorubicin is 0.25-3: 1.
3. The pharmaceutical composition of claim 1, wherein the molar ratio of caffeic acid to doxorubicin is 1.5: 1.
4. A medicament for treating drug-induced cardiomyopathy, which comprises the pharmaceutical composition as claimed in any one of claims 1 to 3 and pharmaceutically acceptable auxiliary materials.
5. The medicament of claim 4, wherein the drug-induced cardiomyopathy is a myocardial injury disease caused by adriamycin.
6. Use of a pharmaceutical composition according to any one of claims 1 to 3 for the preparation of a medicament for the treatment of a drug-induced cardiomyopathy.
7. The use of claim 6, wherein the pharmaceutical cardiomyopathy is a cardiomyopathy induced by doxorubicin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010025091.XA CN111067884A (en) | 2020-01-10 | 2020-01-10 | Pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010025091.XA CN111067884A (en) | 2020-01-10 | 2020-01-10 | Pharmaceutical composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111067884A true CN111067884A (en) | 2020-04-28 |
Family
ID=70322788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010025091.XA Pending CN111067884A (en) | 2020-01-10 | 2020-01-10 | Pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111067884A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
CN101411746A (en) * | 2007-10-19 | 2009-04-22 | 中国科学院上海药物研究所 | Novel use of salvia root extract |
-
2020
- 2020-01-10 CN CN202010025091.XA patent/CN111067884A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
CN101411746A (en) * | 2007-10-19 | 2009-04-22 | 中国科学院上海药物研究所 | Novel use of salvia root extract |
Non-Patent Citations (4)
Title |
---|
ÍÁRKA CHLOPCÍKOVÁ等: "Chemoprotective Effect of Plant Phenolics against Anthracycline-induced Toxicity on Rat Cardiomyocytes Part II. Caffeic, Chlorogenic and Rosmarinic Acids", 《PHYTOTHERAPY RESEARCH》 * |
杨九凌等: "咖啡酸及其衍生物咖啡酸苯乙酯药理作用研究进展", 《中国药学杂志》 * |
王云杰等: "咖啡酸苯乙酯对多柔比星所致心肌损伤大鼠心脏的保护作用及其机制研究", 《中国生化药物杂志》 * |
邹宏斌: "新型芥子醇衍生物、新木脂素及其含氮类似物的设计、合成及生物活性研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116440155B (en) | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug | |
KR20150042274A (en) | Extraction, preparation, and application of plant micro-ribonucleic acid | |
Zhao et al. | Effect of polydatin on neurological function and the Nrf2 pathway during intracerebral hemorrhage | |
Zhang et al. | HJ11 decoction restrains development of myocardial ischemia-reperfusion injury in rats by suppressing ACSL4-mediated ferroptosis | |
CN111067884A (en) | Pharmaceutical composition and application thereof | |
CN111329982B (en) | Novel application of bupleurum tenue granules in combination with chloroquine phosphate | |
CN111658655A (en) | Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug | |
CN111358774A (en) | Astaxanthin and adriamycin combined preparation and application thereof | |
CN108619367A (en) | A kind of Chinese medicine composition is preparing the application in preventing the drug of Acute cardiotoxicity caused by adriamycin | |
CN111939152B (en) | Application of ellagic acid metabolite Urolithin A in preparation of anti-enterovirus drugs | |
Zhou et al. | Protective effects of flavonoids from the leaves of Carya cathayensis Sarg. against H 2 O 2‑induced oxidative damage and apoptosis in vitro | |
CN116115606A (en) | Application of Xanthoxol in preparing medicament for treating cisplatin-induced acute kidney injury | |
US20210154159A1 (en) | Uses of guanidine hydrochloride as a drug for treating cancers/tumors | |
Li et al. | The protective effects of Clerodendranthus spicatus (Thunb.) CY Wu extract on oxidative stress induced by 2, 2'-azo (2-methylpropamidine) dihydrochloride in HL-1 mouse cardiomyocytes | |
RU2741714C1 (en) | Sars-cov-2 replication inhibitor based on a water extract of the fungus inonotus obliquus | |
CN113398175A (en) | Compound traditional Chinese medicine composition for inhibiting dairy cow-derived salmonella and application thereof | |
CN113244276B (en) | Use of Sang Huanghuo Phellinus linteus extract as novel coronavirus therapeutic drug or antiviral agent | |
CN115350181B (en) | Application of small molecular compound in preparation of antiviral infection medicines | |
CN118286196A (en) | Application of salvianolic acid A in preparation of anti-bovine nodular skin disease virus drugs | |
Chen et al. | Protective Mechanism of Velvet Antler Polypeptide on Myocardial Ischemia-Reperfusion Injury in Rats | |
CN116421713A (en) | Anti-aging composition and application thereof | |
Safarpour et al. | Research Article Colchicine Ameliorates 5-Fluorouracil-Induced Cardiotoxicity in Rats | |
Sultana et al. | Evaluation and Comparison of the effects of Low and High doses of Emblica officinalis (Amla) on White Cell Parameters in Animal Model | |
CN117653633A (en) | Application of tetrandrine in preparation of medicines for preventing and treating porcine reproductive and respiratory syndrome | |
CN113440596A (en) | Application of Epitalon in preparation of medicine for relieving acute kidney injury induced by cisplatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200428 |